[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360922-105":59,"doc-detail-360922-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mettl3-and-igf2bp1-associated-m6a-regulation-of-fads2-contributes-to-lipid-droplet-accumulation-and-malignant-progression-in-non-small-cell-lung-cancer","METTL3-and IGF2BP1-associated m6A regulation of FADS2 - contributes to lipid droplet accumulation and malignant progression in non-small cell lung cancer","","Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and key molecular drivers are incompletely defined. This study investigates how the m6A RNA methylation machinery involving the writer METTL3 and the reader IGF2BP1 regulates FADS2, a lipid metabolism-related gene. Using RNA-seq analyses and validation in paired patient tissues, the work links METTL3/IGF2BP1 upregulation to poor survival, demonstrates that suppressing these factors or FADS2 reduces malignant phenotypes, and shows that m6A enrichment in the FADS2 3’-UTR stabilizes transcripts via IGF2BP1 recognition, promoting tumor progression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mettl3-and-igf2bp1-associated-m6a-regulation-of-fads2-contributes-to-lipid-droplet-accumulation-and-malignant-progression-in-non-small-cell-lung-cancer/360922/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mettl3-and-igf2bp1-associated-m6a-regulation-of-fads2-contributes-to-lipid-droplet-accumulation-and-malignant-progression-in-non-small-cell-lung-cancer/360922.png","ImageObject",300,407,{"name":92,"@type":93},"Fans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main biological axis studied in NSCLC in this article?","Question",{"text":112,"@type":113},"The study focuses on the METTL3/IGF2BP1 m6A axis and its regulation of FADS2 expression, linking RNA methylation to lipid accumulation and malignant progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do METTL3 and IGF2BP1 affect NSCLC patient outcomes?",{"text":117,"@type":113},"METTL3 and IGF2BP1 are upregulated in NSCLC tissues and are associated with poor overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism explains how FADS2 promotes NSCLC progression here?",{"text":121,"@type":113},"m6A modification is enriched within the FADS2 3’-UTR where METTL3 and IGF2BP1 bind; loss of METTL3 or IGF2BP1 accelerates FADS2 mRNA decay, while overexpression stabilizes the transcript, increasing lipid droplet accumulation and tumor growth.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360922,1790167904,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892330395,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Article  \nMETTL3-and IGF2BP1-associated m6A regulation of FADS2 contributes to lipid droplet accumulation and malignant progression in non-small cell lung cancer  \nYu Zhang\\#, Lin Wang\\#, Huanhuan Xu, Leping Fang, Yingying Jiang, Weifei Fan, Juqing Xu  \nDepartment of Oncology, Geriatric Hospital of Nanjing Medical University, Jiangsu Province Geriatric Institute, Jiangsu Province Official Hospital, Nanjing, China  \nContributions: (I) Conception and design: J Xu, W Fan; (II) Administrative support: J Xu, W Fan; (III) Provision of study materials or patients: H Xu, L Fang, Y Jiang; (IV) Collection and assembly of data: J Xu, Y Zhang, L Wang; (V) Data analysis and interpretation: J Xu, Y Zhang, L Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \n\\#These authors contributed equally to this work.  \nCorrespondence to: Juqing Xu, PhD, MD; Weifei Fan, MD. Department of Oncology, Geriatric Hospital of Nanjing Medical University, Jiangsu Province Geriatric Institute, Jiangsu Province Official Hospital, No. 65 Jiangsu Road, Nanjing 210024, China. Email: [juqingxu1986@njmu.edu.cn](juqingxu1986@njmu.edu.cn); [fwfei1974@njmu.edu.cn](fwfei1974@njmu.edu.cn).  \nBackground: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide, and its underlying molecular mechanisms remain incompletely defined. N6-methyladenosine (m6A) RNA modification has emerged as a key epigenetic regulator of tumor metabolic reprogramming. However, the roles of the m6A writer methyltransferase-like 3 (METTL3) and the m6A reader insulin-like growth factor  \n2 mRNA-binding protein 1 (IGF2BP1) in NSCLC, particularly in lipid metabolic regulation, remain poorly characterized. The present study aimed to investigate the functional significance of METTL3 and IGF2BP1 in  \nNSCLC, with particular focus on their regulation ofFADS2 expression and lipid metabolism.  \nMethods: Differentially expressed m6A-related genes were identified by analyzing RNA-seq data from The Cancer Genome Atlas (TCGA), followed by validation in 60 paired NSCLC and adjacent normal tissues. Gene and protein expression were examined by qRT-PCR and western blotting, respectively, with immunohistochemistry (IHC) further confirming protein levels in tissue specimens. Functional assays, including colony formation, Transwell migration/invasion, and Oil Red O staining, were performed in A549 and H1299 cells following METTL3, IGF2BP1, or FADS2 perturbation. The m6A modification on FADS2 mRNA was assessed by MeRIP-qPCR, and its association with METTL3 and IGF2BP1 was examined by RIP-qPCR. RNA stability was evaluated via actinomycin D chase assays, and rescue experiments were conducted through co-transfection of shRNA and overexpression constructs. The in vivo role of FADS2 was  \nassessed using a xenograft tumor model.  \nResults: METTL3 and IGF2BP1 were significantly upregulated in NSCLC tissues and were associated with poor overall survival. Silencing either gene inhibited NSCLC cell proliferation, migration, and invasion.  \nFADS2 expression was markedly elevated in NSCLC and positively correlated with METTL3 and IGF2BP1 expression. Knockdown of FADS2 reduced lipid droplet accumulation and suppressed malignant phenotypesin vitro, while significantly inhibiting tumor growth in vivo. Mechanistically, m6A modification was enriched within the 3’-UTR of FADS2 mRNA, where both METTL3 and IGF2BP1 were found to bind. Loss of METTL3 or IGF2BP1 accelerated FADS2 mRNA decay, whereas their overexpression enhanced transcript stability. Rescue experiments further confirmed that METTL3 and IGF2BP1 cooperatively regulate FADS2  \nexpression and thereby promote NSCLC progression.  \nConclusions: METTL3-mediated m6A modification of FADS2 transcripts is recognized by IGF2BP1, resulting in enhanced mRNA stability, increased lipid accumulation, and NSCLC progression. Our findings suggest that the METTL3/IGF2BP1-FADS2 axis contributes to lipid metabol","cbCaimyq7k7H2chp","https://ap.wps.com/l/cbCaimyq7k7H2chp","pdf",13873495,21,"English","# Introduction\n## Background on NSCLC and m6A regulation\n# Highlight box\n## Key findings\n## What is known and what is new?","[{\"question\":\"What is the main biological axis studied in NSCLC in this article?\",\"answer\":\"The study focuses on the METTL3/IGF2BP1 m6A axis and its regulation of FADS2 expression, linking RNA methylation to lipid accumulation and malignant progression.\"},{\"question\":\"How do METTL3 and IGF2BP1 affect NSCLC patient outcomes?\",\"answer\":\"METTL3 and IGF2BP1 are upregulated in NSCLC tissues and are associated with poor overall survival.\"},{\"question\":\"What mechanism explains how FADS2 promotes NSCLC progression here?\",\"answer\":\"m6A modification is enriched within the FADS2 3’-UTR where METTL3 and IGF2BP1 bind; loss of METTL3 or IGF2BP1 accelerates FADS2 mRNA decay, while overexpression stabilizes the transcript, increasing lipid droplet accumulation and tumor growth.\"}]","METTL3-and IGF2BP1-associated m6A regulation of FADS2 - contributes to lipid droplet accumulation and malignant progression in non-small cell lung cancer | PDF",1790142035,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6322d58f0c8494d1ea29dc2814fcf3f8.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe1aa867947d467193d2d5af798c7258.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/524d6766c08522836bdf5838c089aba0.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7136720d952d1d385836e2c72b69b91.webp",980,1283]